Drug company won’t cut its $750-per-pill price; rival’s 99-cent version getting snatched up
After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.
Instead, the small biotech company says it’s reducing the price for hospitals by up to 50% for its Daraprim, which treats a rare parasitic infection that mainly strikes pregnant women and HIV patients.
Then a pharmacy that compounds prescription drugs for individual patients stepped in and started selling a capsule version for 99 cents. Imprimis Pharmaceuticals says orders are pouring in from doctors and it says it has dispensed more than 2,500 capsules in barely a month.
MORE FROM BUSINESS
Your guide to our new economic reality.
Get our free business newsletter for insights and tips for getting by.
You may occasionally receive promotional content from the Los Angeles Times.